Skip to Content

BrainsWay Ltd BRSYF

Morningstar Rating
$2.47 +0.62 (33.51%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BRSYF is trading at a 39% discount.
Price
$2.45
Fair Value
$4.32
Uncertainty
Extreme
1-Star Price
$1.40
5-Star Price
$6.25
Economic Moat
Pnrjl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BRSYF is a good fit for your portfolio.

Trading Information

Previous Close Price
$1.85
Day Range
$2.472.47
52-Week Range
$0.902.97
Bid/Ask
$1.45 / $9.99
Market Cap
$82.19 Mil
Volume/Avg
250 / 2,251

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.58
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Core
Total Number of Employees
106

Valuation

Metric
BRSYF
Price/Earnings (Normalized)
Price/Book Value
2.21
Price/Sales
2.58
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
BRSYF
Quick Ratio
5.10
Current Ratio
5.68
Interest Coverage
−126.44
Quick Ratio
BRSYF

Profitability

Metric
BRSYF
Return on Assets (Normalized)
−4.52%
Return on Equity (Normalized)
−7.40%
Return on Invested Capital (Normalized)
−10.35%
Return on Assets
BRSYF
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesSyhdhlygkXlltp$185.5 Bil
SYK
Stryker CorpPtmsdfffpHtvt$128.2 Bil
MDT
Medtronic PLCTcpykgljqSsqrpqc$106.7 Bil
BSX
Boston Scientific CorpKgcfzfzsYfnnks$99.0 Bil
DXCM
DexCom IncTkybrrxxnQcym$53.1 Bil
EW
Edwards Lifesciences CorpXjlxbskpgSzcgjxk$52.8 Bil
ZBH
Zimmer Biomet Holdings IncXybnsnxsppBqfhn$24.9 Bil
ALGN
Align Technology IncGsqfgbfQllsts$23.5 Bil
PHG
Koninklijke Philips NV ADRNbpkqywjBpmxdzq$18.9 Bil
PODD
Insulet CorpMpjqxgdfZpqspwy$11.7 Bil

Sponsor Center